Millennium Management
BCRX icon

Millennium Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Millennium Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,800
Closed -$474K – 6115
2023
Q1 		$474K Buy
+56,800
New +$547K ﹤0.01% 4641

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management's BCRX Position: Q1 2026 in Review

Millennium Management increased its BioCryst Pharmaceuticals (BCRX) stake by 36% in Q1 2026, buying an estimated $389K and bringing the position to 187,721 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3982.

Millennium Management first reported a position in BCRX in Q3 2013 and has held it in 50 quarters since. The position peaked at $37.3M in Q2 2023. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Millennium Management held 187,721 shares of BioCryst Pharmaceuticals worth $1.79M as of Q1 2026.
  • Millennium Management bought 50,095 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $389K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3982 holding.
  • Millennium Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
  • Millennium Management's BioCryst Pharmaceuticals position peaked at $37.3M in Q2 2023.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.